176 related articles for article (PubMed ID: 35648671)
1. Non-metastatic castration-resistant prostate cancer: the evolving treatment landscape and role of nurse specialists.
Hunnisett A; Victor D
Br J Nurs; 2022 May; 31(10):S4-S13. PubMed ID: 35648671
[TBL] [Abstract][Full Text] [Related]
2. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use.
Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST
J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
4. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
5. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
[TBL] [Abstract][Full Text] [Related]
6. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
Saad F; Bögemann M; Suzuki K; Shore N
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):323-334. PubMed ID: 33558665
[TBL] [Abstract][Full Text] [Related]
7. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
8. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract][Full Text] [Related]
9. Darolutamide for treatment of castration-resistant prostate cancer.
Rhea LP; Mendez-Marti S; Aragon-Ching JB
Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
[TBL] [Abstract][Full Text] [Related]
10. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A
Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
[TBL] [Abstract][Full Text] [Related]
11. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
Tartarone A; Lerose R; Tartarone M
Med Oncol; 2022 May; 39(7):107. PubMed ID: 35553247
[TBL] [Abstract][Full Text] [Related]
12. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Carles J; Medina-Lopez RA; Puente J; Gómez-Ferrer Á; Nebra JC; Sáez Medina MI; Ribal MJ; Antolín AR; Álvarez-Ossorio JL; Suárez Novo JF; Agut CM; Srinivasan S; Ortiz J; Fizazi K
Future Oncol; 2023 Apr; 19(12):819-828. PubMed ID: 37222151
[TBL] [Abstract][Full Text] [Related]
13. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Scott LJ
Target Oncol; 2020 Dec; 15(6):791-799. PubMed ID: 33237495
[TBL] [Abstract][Full Text] [Related]
14. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
[No Abstract] [Full Text] [Related]
15. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
Shore ND; Stenzl A; Pieczonka C; Klaassen Z; Aronson WJ; Karsh L; Ryan CJ; Ortiz J; Srinivasan S; Mohamed AF; Verholen F
BJU Int; 2023 Apr; 131(4):452-460. PubMed ID: 36087070
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
17. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
18. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
19. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
20. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Petrenciuc O; Snapir A; Sarapohja T; Smith MR;
N Engl J Med; 2020 Sep; 383(11):1040-1049. PubMed ID: 32905676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]